New treatments for HIV that work against drug-resistant strains
Official title: Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
Funded at Emory University · NIH-10977647 · Data updated 2026-11-12
This study is testing new, super-strong medicines that aim to stop HIV from spreading, especially in cases where current treatments aren't working well, so that patients can have better and safer options for managing their health.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $626,362 |
| NIH project number | 4R37AI076119-17 |
| Project ID | NIH-10977647 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV, especially those who have not responded well to existing treatments.
✕Less likely to help
Patients who are not infected with HIV or those who have already achieved viral suppression with current therapies may not benefit from this research.
What this research studies
This research focuses on developing ultrapotent inhibitors that target HIV, including strains resistant to current treatments. The approach involves a novel mechanism that blocks the replication of the virus by interfering with a specific step in the HIV life cycle. Patients may benefit from longer-acting and less toxic therapies that could improve their quality of life and treatment outcomes. The research includes pre-clinical and clinical trials to evaluate the effectiveness and safety of these new drugs.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer HIV treatments, particularly for those with drug-resistant strains.
How similar studies have gone: Previous research has shown promise with similar mechanisms targeting HIV, indicating potential for success in this area.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Sarafianos, Stefan G — Emory University
- Study coordinator: Sarafianos, Stefan G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.